Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019

Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019

Summary

According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019'; Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Tumor necrosis factor receptor 1 (TNFR1) is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFalpha). This receptor activates NF-kappaB, mediate apoptosis and function as a regulator of inflammation. Mutations in this receptor were found to be associated with tumor necrosis factor associated periodic syndrome (TRAPS).

The report 'Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 2, 4 and 3 respectively.

Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Central Nervous System, Gastrointestinal, Immunology, Undisclosed, Infectious Disease and Ophthalmology which include indications Atopic Dermatitis (Atopic Eczema), Multiple Sclerosis, Non-Alcoholic Steatohepatitis (NASH), Soft Tissue Sarcoma, Unspecified, Actinic (Solar) Keratosis, Alzheimer's Disease, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Colon Cancer, Gastrointestinal Tract Cancer, Genital Warts (Condylomata Acuminata), Glioma, Inflammation, Intermediate Uveitis, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Endocrine Tumor, Posterior Uveitis, Prostate Cancer, Psoriasis, Retinitis Pigmentosa (Retinitis), Rheumatoid Arthritis, Solid Tumor, Thyroid Cancer and Warts.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope